New CVS Hub Stores, NASH Drugs, Liquid Biopsy, Illumina Chip, Smokeless Tobacco Reduction, Among Developments at JPM and Biotech Showcase

New CVS Hub Stores, NASH Drugs, Liquid Biopsy, Illumina Chip, Smokeless Tobacco Reduction, Among Developments at JPM and Biotech Showcase

Drugs for an underserved liver disease class, continued liquid biopsy development, a new chip to improve reads and run lengths for NGS and many company updates were on Kalorama's radar at the 37th J.P. Morgan Healthcare Conference in San Francisco last week.

  • by Bruce Carlson
  • January 7 2019


$115 Billion in China Biotech Investments, New Apps and Devices, Biogen ALZ Deals Lead Early JPMHC / Biotech Showcase News

China biotech numbers from 2018 roll in and the news is good, a headache app and other trends before the show truly begins.

  • by Bruce Carlson
  • January 2 2019
  • IVD


2019 Biotech Showcase Developments of Note, with a Particular IVD Focus

2019 Biotech Showcase Developments of Note, with a Particular IVD Focus

Kalorama Information will be covering the 2019 Biotech Showcase, which is concurrent with the J.P. Morgan Healthcare Conference, in San Francisco January 7-9th. Here are some interesting developments that we will report on as the meeting proceeds.

  • by Bruce Carlson
  • December 26 2018


Drive for Prevention to Fuel Food Safety Diagnostics

This article, based on our Food Safety Diagnostics report, looks at the trends in food safety diagnostics. IVD manufacturers increasingly see food safety as an additional marketplace for their devices.

  • by Bruce Carlson
  • December 17 2018


IVD in 2019: Eight Out-of-the-Box Predictions

IVD in 2019: Eight Out-of-the-Box Predictions

From our various publications and analysts, a few trends that haven't been reported on extensively. Look for these to unfold in 2019.

  • by Bruce Carlson
  • December 10 2018


Smartphones and IVD: Early, But Getting There

Smartphones and IVD: Early, But Getting There

Development-stage projects - and a few products- mark the current field of smartphone in-vitro combinations, per Kalorama's new report.

  • by Aaron Hackle
  • December 6 2018


#BIOMEDevice2018: Kalorama Presents IVD Findings, Sums Up Best Opportunities in Testing, Biosensors and AI Discussed

#BIOMEDevice2018:  Kalorama Presents IVD Findings, Sums Up Best Opportunities in Testing, Biosensors and AI Discussed

At BIOMEDevice San Jose, leading device, testing, accessories and contract manufacturing firms presented their latest technology. Kalorama Information was there and presented the IVD market picture from its latest Worldwide Market for In Vitro Diagnostic Test report. Firms with new MI surgery, biosensor technologies and other products exhibited.

  • by Bruce Carlson
  • December 4 2018


Where Clinical Sequencing Is Now

Where Clinical Sequencing Is Now

Do NGS tests really offer useful insights beyond routine testing for targeted mutations? Are the high costs justified? Should everyone be sequenced? And what will happen when the price drops seriously? We discuss these topics in this article.

  • by Bruce Carlson
  • November 30 2018
  • HIV
  • IVD


The Latest Developments in HIV Diagnostic Testing

The Latest Developments in HIV Diagnostic Testing

HIV remains a deadly disease, but fortunately, in vitro diagnostic solutions abound for its detection and treatment progress-tracking. From utilizing dentists, to making tests available on more analyzer systems, we track the developments in HIV IVD in this articlee. More information can be found in our Worldwide Market for In Vitro Diagnostics Tests, 11th Edition

  • by Bruce Carlson
  • November 26 2018


Kalorama To Present IVD Market Findings at BIOMEDevice

Kalorama To Present IVD Market Findings at BIOMEDevice

Direct to Consumer Testing, The Status of Point of Care, Novel Biomarkers, Wearables, AI and Robotics, New EU Regulations - Kalorama will speak to these point and present top-level findings from our 11th Edition Worldwide IVD Market Study at the meeting in San Jose, CA, Dec. 4-6.